Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Nuclear Cardiology
Published in: Journal of Nuclear Cardiology 4/2019

01-08-2019 | Review Article

Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?

Author: Paco E. Bravo, MD

Published in: Journal of Nuclear Cardiology | Issue 4/2019

Login to get access

Abstract

Coronary microvascular dysfunction and, its functional consequence, myocardial ischemia are common pathologic features in patients with hypertrophic cardiomyopathy (HCM). Both have been commonly invoked as potential triggers of and/or contributors to the underlying pathophysiological processes leading to heart failure, and malignant ventricular arrhythmias. Positron emission tomography (PET) with myocardial blood flow quantification provides a unique opportunity to evaluate the integrity and function of the coronary microcirculation in HCM. The purpose of the present review is to summarize all the pertinent literature and future perspectives of the role of PET in the evaluation and risk stratification of patients with HCM.
Appendix
Available only for authorised users
Literature
1.
Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92:785-9.CrossRefPubMed
2.
Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;8:545-57.CrossRefPubMed
3.
Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Morphologic evidence for “small vessel disease” in patients with hypertrophic cardiomyopathy. Z Kardiol 1987;76:91-100.PubMed
4.
Johansson B, Morner S, Waldenstrom A, Stal P. Myocardial capillary supply is limited in hypertrophic cardiomyopathy: A morphological analysis. Int J Cardiol 2008;126:252-7.CrossRefPubMed
5.
Krams R, Kofflard MJ, Duncker DJ, Von Birgelen C, Carlier S, Kliffen M, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 1998;97:230-3.CrossRefPubMed
6.
Cannon RO 3rd, Rosing DR, Maron BJ, Leon MB, Bonow RO, Watson RM, et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: Contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 1985;71:234-43.CrossRefPubMed
7.
Pak PH, Maughan WL, Baughman KL, Kieval RS, Kass DA. Mechanism of acute mechanical benefit from VDD pacing in hypertrophied heart: Similarity of responses in hypertrophic cardiomyopathy and hypertensive heart disease. Circulation 1998;98:242-8.CrossRefPubMed
8.
Elliott PM, Kaski JC, Prasad K, Seo H, Slade AK, Goldman JH, et al. Chest pain during daily life in patients with hypertrophic cardiomyopathy: An ambulatory electrocardiographic study. Eur Heart J 1996;17:1056-64.CrossRefPubMed
9.
Cannon RO 3rd, Dilsizian V, O’Gara PT, Udelson JE, Schenke WH, Quyyumi A, et al. Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation 1991;83:1660-7.CrossRefPubMed
10.
Bengel FM, Higuchi T, Javadi MS, Lautamaki R. Cardiac positron emission tomography. J Am Coll Cardiol 2009;54:1-15.CrossRefPubMed
11.
Bravo PE, Bengel FM. The role of cardiac PET in translating basic science into the clinical arena. J Cardiovasc Transl Res 2011;4:425-36.CrossRefPubMed
12.
Schelbert HR, Phelps ME, Hoffman EJ, Huang SC, Selin CE, Kuhl DE. Regional myocardial perfusion assessed with N-13 labeled ammonia and positron emission computerized axial tomography. Am J Cardiol 1979;43:209-18.CrossRefPubMed
13.
Gould KL, Schelbert HR, Phelps ME, Hoffman EJ. Noninvasive assessment of coronary stenoses with myocardial perfusion imaging during pharmacologic coronary vasodilatation. V. Detection of 47 percent diameter coronary stenosis with intravenous nitrogen-13 ammonia and emission-computed tomography in intact dogs. Am J Cardiol 1979;43:200-8.CrossRefPubMed
14.
Shah A, Schelbert HR, Schwaiger M, Henze E, Hansen H, Selin C, et al. Measurement of regional myocardial blood flow with N-13 ammonia and positron-emission tomography in intact dogs. J Am Coll Cardiol 1985;5:92-100.CrossRefPubMed
15.
Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary-artery stenosis. N Engl J Med 1994;330:1782-8.CrossRefPubMed
16.
Di Carli M, Czernin J, Hoh CK, Gerbaudo VH, Brunken RC, Huang SC, et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation 1995;91:1944-51.CrossRefPubMed
17.
Czernin J, Muller P, Chan S, Brunken RC, Porenta G, Krivokapich J, et al. Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation 1993;88:62-9.CrossRefPubMed
18.
Sdringola S, Johnson NP, Kirkeeide RL, Cid E, Gould KL. Impact of unexpected factors on quantitative myocardial perfusion and coronary flow reserve in young, asymptomatic volunteers. JACC Cardiovasc Imaging 2011;4:402-12.CrossRefPubMed
19.
Murthy VL, Bateman TM, Beanlands RS, Berman DS, Borges-Neto S, Chareonthaitawee P, et al. Clinical quantification of myocardial blood flow using PET: Joint position paper of the SNMMI cardiovascular council and the ASNC. J Nucl Med 2018;59:273-93.CrossRefPubMed
20.
Bravo PE, Pinheiro A, Higuchi T, Rischpler C, Merrill J, Santaularia-Tomas M, et al. PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy. J Nucl Med 2012;53:407-14.CrossRefPubMed
21.
Olivotto I, Girolami F, Sciagra R, Ackerman MJ, Sotgia B, Bos JM, et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol 2011;58:839-48.CrossRefPubMed
22.
Knaapen P, Germans T, Camici PG, Rimoldi OE, ten Cate FJ, ten Berg JM, et al. Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 2008;294:H986-93.CrossRefPubMed
23.
Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA, et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: New insights from multiparametric magnetic resonance imaging. Circulation 2007;115:2418-25.CrossRefPubMed
24.
Tanaka M, Fujiwara H, Onodera T, Wu DJ, Matsuda M, Hamashima Y, et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 1987;75:1130-9.CrossRefPubMed
25.
Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: The interrelation of disarray, fibrosis, and small vessel disease. Heart 2000;84:476-82.CrossRefPubMedPubMedCentral
26.
Sotgia B, Sciagra R, Olivotto I, Casolo G, Rega L, Betti I, et al. Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. J Nucl Med 2008;49:1090-6.CrossRefPubMed
27.
Bravo PE, Zimmerman SL, Luo HC, Pozios I, Rajaram M, Pinheiro A, et al. Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2013;6:210-7.CrossRefPubMedPubMedCentral
28.
Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: Correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol 2009;54:242-9.CrossRefPubMed
29.
Udelson JE, Bonow RO, O’Gara PT, Maron BJ, Van Lingen A, Bacharach SL, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989;79:1052-60.CrossRefPubMed
30.
Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35.CrossRefPubMed
31.
Lorenzoni R, Gistri R, Cecchi F, Olivotto I, Chiriatti G, Elliott P, et al. Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. Am Heart J 1998;136:972-81.CrossRefPubMed
32.
Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: Pathologic evidence of myocardial ischemia. Hum Pathol 2000;31:988-98.CrossRefPubMed
33.
Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;22:796-804.CrossRefPubMed
34.
Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation 2003;108:2342-8.CrossRefPubMed
35.
Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124:2761-96.CrossRefPubMed
36.
Olivotto I, Cecchi F, Gistri R, Lorenzoni R, Chiriatti G, Girolami F, et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006;47:1043-8.CrossRefPubMed
37.
Sciagra R, Sotgia B, Olivotto I, Cecchi F, Nistri S, Camici PG, et al. Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. J Nucl Cardiol 2009;16:92-6.CrossRefPubMed
38.
Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014;130:484-95.CrossRefPubMed
39.
Yamada M, Elliott PM, Kaski JC, Prasad K, Gane JN, Lowe CM, et al. Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. Eur Heart J 1998;19:500-7.CrossRefPubMed
40.
Castagnoli H, Ferrantini C, Coppini R, Passeri A, Baldini K, Berti V, et al. Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: A 2016 reappraisal. Eur J Nucl Med Mol Imaging 2016;43:2413-22.CrossRefPubMed
41.
42.
Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovascular Imaging 2012;5:370-7.CrossRefPubMed
43.
O’Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:867-74.CrossRefPubMed
44.
Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008;1:184-91.CrossRefPubMed
45.
Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:875-87.CrossRefPubMed
46.
Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD, Klocke FJ, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;40:2156-64.CrossRefPubMed
47.
Lamke GT, Allen RD, Edwards WD, Tazelaar HD, Danielson GK. Surgical pathology of subaortic septal myectomy associated with hypertrophic cardiomyopathy. A study of 204 cases (1996-2000). Cardiovasc Pathol 2003;12:149-58.CrossRefPubMed
48.
Allen RD, Edwards WD, Tazelaar HD, Danielson GK. Surgical pathology of subaortic septal myectomy not associated with hypertrophic cardiomyopathy: A study of 98 cases (1996-2000). Cardiovasc Pathol 2003;12:207-15.CrossRefPubMed
49.
Higuchi T, Abletshauser C, Nekolla SG, Schwaiger M, Bengel FM. Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease. Microcirculation 2007;14:805-12.CrossRefPubMed
50.
Neglia D, Fommei E, Varela-Carver A, Mancini M, Ghione S, Lombardi M, et al. Perindopril and indapamide reverse coronary microvascular remodelling and improve flow in arterial hypertension. J Hypertens 2011;29:364-72.CrossRefPubMed
51.
Kyriakidis M, Triposkiadis F, Dernellis J, Androulakis AE, Mellas P, Kelepeshis GA, et al. Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy. Circulation 1998;97:1342-7.CrossRefPubMed
52.
Spoladore R, Maron MS, D’Amato R, Camici PG, Olivotto I. Pharmacological treatment options for hypertrophic cardiomyopathy: High time for evidence. Eur Heart J 2012;33:1724-33.CrossRefPubMed
53.
54.
Kellman P, Wilson JR, Xue H, Bandettini WP, Shanbhag SM, Druey KM, et al. Extracellular volume fraction mapping in the myocardium, Part 2: Initial clinical experience. J Cardiovasc Magn Reson 2012;14:64.CrossRefPubMedPubMedCentral
55.
Collier P, Phelan D, Klein A. A test in context: Myocardial strain measured by speckle-tracking echocardiography. J Am Coll Cardiol 2017;69:1043-56.CrossRefPubMed
56.
Hindieh W, Chan R, Rakowski H. Complementary role of echocardiography and cardiac magnetic resonance in hypertrophic cardiomyopathy. Curr Cardiol Rep 2017;19:81.CrossRefPubMed
Metadata
Title
Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?
Author
Paco E. Bravo, MD
Publication date
01-08-2019
Publisher
Springer International Publishing
Published in
Journal of Nuclear Cardiology / Issue 4/2019
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-018-1298-4

Other articles of this Issue 4/2019

Journal of Nuclear Cardiology 4/2019 Go to the issue

International Corner

How do we establish cardiac sympathetic nervous system imaging with 123I-mIBG in clinical practice? Perspectives and lessons from Japan and the US

Editorial

Artifact-free quantitative cardiovascular PET/MR imaging: An impossible dream?

Supplement to Journal of Nuclear Cardiology

Abstracts of Original Contributions ASNC2019 The 24th Annual Scientific Session of the American Society of Nuclear Cardiology

Correction

Correction to: Comparison of two software systems for quantification of myocardial blood flow in patients with hypertrophic cardiomyopathy

Editorial

Detection of chemotherapy-induced cardiotoxicity with antimyosin pretargeted imaging

Images that Teach

Early infected aneurysm with 18F-FDG uptake prior to substantial anatomical changes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits